ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3021% above fair value

$10.75+0.53 (+5.19%)

Close on Nov 13, 2026Market cap $97.63MP/E 53.8Yield –

ImmuCell total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

ImmuCell's total debt was $7.90M at Sep 30, 2026. For fiscal 2025 it was $9.10M, down 13.7% from the year before. The highest annual figure on record is $22.40M in fiscal 2023.

Annual total debt

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$9.10M	-13.7%
FY2024	Dec 31, 2024	$10.54M	-53.0%
FY2023	Dec 31, 2023	$22.40M	+17.1%
FY2022	Dec 31, 2022	$19.13M	+124.5%
FY2019	Dec 31, 2019	$8.52M	-9.2%
FY2018	Dec 31, 2018	$9.38M	+3.3%
FY2017	Dec 31, 2017	$9.09M	–

Quarterly total debt

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$7.90M	-16.8%
Q2 FY2026	Jun 30, 2026	$8.30M	-15.3%
Q1 FY2026	Mar 31, 2026	$8.70M	-14.4%
Q4 FY2025	Dec 31, 2025	$9.10M	-13.7%
Q3 FY2025	Sep 30, 2025	$9.49M	-12.9%
Q2 FY2025	Jun 30, 2025	$9.80M	-53.6%
Q1 FY2025	Mar 31, 2025	$10.17M	-53.2%
Q4 FY2024	Dec 31, 2024	$10.54M	-53.0%
Q3 FY2024	Sep 30, 2024	$10.90M	-11.5%
Q2 FY2024	Jun 30, 2024	$21.11M	+10.4%
Q1 FY2024	Mar 31, 2024	$21.72M	+122.7%
Q4 FY2023	Dec 31, 2023	$22.40M	+126.4%
Q3 FY2023	Sep 30, 2023	$12.32M	+43.2%
Q4 FY2022	Dec 31, 2022	$19.13M	+124.5%
Q3 FY2020	Sep 30, 2020	$9.75M	+11.6%
Q2 FY2020	Jun 30, 2020	$9.90M	+10.5%
Q1 FY2020	Mar 31, 2020	$8.60M	-6.2%
Q4 FY2019	Dec 31, 2019	$8.52M	-9.2%
Q3 FY2019	Sep 30, 2019	$8.74M	-8.9%
Q2 FY2019	Jun 30, 2019	$8.95M	-3.1%
Q1 FY2019	Mar 31, 2019	$9.17M	-1.6%
Q4 FY2018	Dec 31, 2018	$9.38M	+3.3%
Q3 FY2018	Sep 30, 2018	$9.59M	–
Q2 FY2018	Jun 30, 2018	$9.24M	–
Q1 FY2018	Mar 31, 2018	$9.31M	–
Q4 FY2017	Dec 31, 2017	$9.09M	–